Cardio, Inc., makes and sells Drawdown, the most prescribed name-brand heart medication. Emitate Corporation has the potential to make a generic version of the same drug. Cardio pays Emitate not to sell its product. This is most likely

Question

Quizplus · Accepted Answer

This situation is likely a per se violation of the Sherman Act because it involves a "pay-for-delay" agreement, where a brand-name drug manufacturer pays a potential generic competitor to delay entering the market, which is considered an anticompetitive practice.